Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.-Reference-Cited by-同舟云学术

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:8063-8063
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Arkenau Hendrik-Tobias¹,Sachdev Jasgit C.²,Mita Monica M.³,Dziadziuszko Rafal⁴,Lin Chia-Chi⁵,Yang James CH⁶,Infante Jeffrey R.⁷,Anthony Stephen Patrick⁸,Voskoboynik Mark⁹,Su Wu-Chou¹⁰,De Castro Javier¹¹,Natale Ronald B.¹²,Zhang Zhi-Yi¹³,Hughes Lorraine¹³,Bobilev Dmitri¹⁴,Weiss Glen J.¹⁵

Affiliation:

1. Sarah Cannon Research Institute, London, United Kingdom

2. Scottsdale Healthcare, Paradise Valley, AZ

3. Cedars-Sinai Med Ctr, Los Angeles, CA

4. Medical University of Gdansk, Gdansk, Poland

5. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

6. National Cancer Institute Taiwan, Taipei, Taiwan

7. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

8. Evergreen Hem/Onc, Spokane, WA

9. Sarah Cannon Research Institute UK, London, United Kingdom

10. National Cheng Kung University Hospital, Tainan, Taiwan

11. Hospital La Paz, Madrid, Spain